Synthesis of a Peptide-universal Nucleotide Antigen: Towards Next-generation Antibodies to Detect Topoisomerase I-DNA Covalent Complexes

Overview

Journal Org Biomol Chem

Publisher Royal Society of Chemistry

Specialties Biochemistry
Chemistry

Date 2016 Apr 27

PMID 27113574

Citations 1

Authors

Angela L Perkins

Kevin L Peterson

Thomas G Beito

Karen S Flatten

Scott H Kaufmann

Daniel A Harki

Affiliations

Soon will be listed here.

Abstract

The topoisomerase (topo) I-DNA covalent complex represents an attractive target for developing diagnostic antibodies to measure responsiveness to drugs. We report a new antigen, peptide , and four murine monoclonal antibodies raised against that exhibit excellent specificity for recognition of in comparison to structurally similar peptides by enzyme-linked immunosorbent assays. Although topo I-DNA complex detection was not achieved in cellular samples by these new antibodies, a new strategy for antigen design is reported.

Citing Articles

Reassessing APOBEC3G Inhibition by HIV-1 Vif-Derived Peptides.

Richards C, Li M, Perkins A, Rathore A, Harki D, Harris R J Mol Biol. 2016; 429(1):88-96.

PMID: 27887868 PMC: 5186364. DOI: 10.1016/j.jmb.2016.11.012.

References

Patel A, Flatten K, Peterson K, Beito T, Schneider P, Perkins A . Immunodetection of human topoisomerase I-DNA covalent complexes. Nucleic Acids Res. 2016; 44(6):2816-26. PMC: 4824114. DOI: 10.1093/nar/gkw109. View

Braun M, Richman S, Quirke P, Daly C, Adlard J, Elliott F . Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial. J Clin Oncol. 2008; 26(16):2690-8. DOI: 10.1200/JCO.2007.15.5580. View

Fiorani P, Amatruda J, Silvestri A, Butler R, Bjornsti M, Benedetti P . Domain interactions affecting human DNA topoisomerase I catalysis and camptothecin sensitivity. Mol Pharmacol. 1999; 56(6):1105-15. DOI: 10.1124/mol.56.6.1105. View

Hedberg C, Itzen A . Molecular perspectives on protein adenylylation. ACS Chem Biol. 2014; 10(1):12-21. DOI: 10.1021/cb500854e. View

Zhang A, Lyu Y, Lin C, Zhou N, Azarova A, Wood L . A protease pathway for the repair of topoisomerase II-DNA covalent complexes. J Biol Chem. 2006; 281(47):35997-6003. DOI: 10.1074/jbc.M604149200. View

Pommier Y . Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer. 2006; 6(10):789-802. DOI: 10.1038/nrc1977. View

Smit C, Blumer J, Eerland M, Albers M, Muller M, Goody R . Efficient synthesis and applications of peptides containing adenylylated tyrosine residues. Angew Chem Int Ed Engl. 2011; 50(39):9200-4. DOI: 10.1002/anie.201103203. View

Staker B, Hjerrild K, Feese M, Behnke C, Burgin Jr A, Stewart L . The mechanism of topoisomerase I poisoning by a camptothecin analog. Proc Natl Acad Sci U S A. 2002; 99(24):15387-92. PMC: 137726. DOI: 10.1073/pnas.242259599. View

Li C, Averboukh L, Pardee A . beta-Lapachone, a novel DNA topoisomerase I inhibitor with a mode of action different from camptothecin. J Biol Chem. 1993; 268(30):22463-8. View

10.

Champoux J . DNA topoisomerases: structure, function, and mechanism. Annu Rev Biochem. 2001; 70:369-413. DOI: 10.1146/annurev.biochem.70.1.369. View

11.

Staker B, Feese M, Cushman M, Pommier Y, Zembower D, Stewart L . Structures of three classes of anticancer agents bound to the human topoisomerase I-DNA covalent complex. J Med Chem. 2005; 48(7):2336-45. DOI: 10.1021/jm049146p. View

12.

de StGroth S, Scheidegger D . Production of monoclonal antibodies: strategy and tactics. J Immunol Methods. 1980; 35(1-2):1-21. DOI: 10.1016/0022-1759(80)90146-5. View

13.

Ding H, Hackbarth J, Schneider P, Peterson K, Meng X, Dai H . Cytotoxicity of farnesyltransferase inhibitors in lymphoid cells mediated by MAPK pathway inhibition and Bim up-regulation. Blood. 2011; 118(18):4872-81. PMC: 3208295. DOI: 10.1182/blood-2011-02-334870. View

14.

Loakes D . Survey and summary: The applications of universal DNA base analogues. Nucleic Acids Res. 2001; 29(12):2437-47. PMC: 55727. DOI: 10.1093/nar/29.12.2437. View

15.

de Lucas Chazin E, Reis R, Vellasco Junior W, Moor L, Vasconcelos T . An overview on the development of new potentially active camptothecin analogs against cancer. Mini Rev Med Chem. 2014; 14(12):953-62. DOI: 10.2174/1389557514666141029233037. View

16.

Muller M, Albers M, Itzen A, Hedberg C . Exploring adenylylation and phosphocholination as post-translational modifications. Chembiochem. 2013; 15(1):19-26. DOI: 10.1002/cbic.201300508. View

17.

Mattern M, Mong S, Bartus H, Mirabelli C, Crooke S, Johnson R . Relationship between the intracellular effects of camptothecin and the inhibition of DNA topoisomerase I in cultured L1210 cells. Cancer Res. 1987; 47(7):1793-8. View

18.

Kaufmann S . Reutilization of immunoblots after chemiluminescent detection. Anal Biochem. 2001; 296(2):283-6. DOI: 10.1006/abio.2001.5313. View

19.

Kummar S, Kinders R, Gutierrez M, Rubinstein L, Parchment R, Phillips L . Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies. J Clin Oncol. 2009; 27(16):2705-11. PMC: 2739635. DOI: 10.1200/JCO.2008.19.7681. View

20.

Hsiang Y, Liu L, Wall M, Wani M, Nicholas A, Manikumar G . DNA topoisomerase I-mediated DNA cleavage and cytotoxicity of camptothecin analogues. Cancer Res. 1989; 49(16):4385-9. View